December 2016
-
Intranasal drug developer Vistagen has announced the appointment of Elissa Cote as Chief Corporate Development Officer. According to her LinkedIn page, Cote served as a strategic advisor to Narcan nasal spray developer Emergent Biosolutions from January 2023 to… Read more . . .
-
According to Theravance Biopharma, a marketing application submitted to the Chinese National Medical Products Administration (NMPA) by Viatris for Yupelri revefenacin inhalation solution for the treatment of COPD has been approved. In November 2023, Theravance and Viatris announced… Read more . . .
-
Bryn Pharma announced that it has initiated a PK/PD trial of its epinephrine spray in an updated delivery device, with topline data expected in the third quarter of this year. The company said that the… Read more . . .
-
GH Research announced that it has submitted its response to a clinical hold of an IND for the company’s GH001 inhaled mebufotenin (5-MeO-DMT) for the treatment of treatment-resistant depression. The FDA cited “Insufficient information to… Read more . . .
-
CDMO Kindeva has announced an agreement with Canadian company Rocket Science Health (RSH) for development of RSH’s “Olfactory Delivery Device,” which is designed for high deposition of drug to the olfactory clefts. Kindeva, which acquired nasal… Read more . . .
-
Lupin announced that it has signed an agreement with Sino Universal Pharmaceuticals for commercialization of Lupin’s tiotropium dry powder inhaler in China for the treatment of COPD. Per the agreement, Sino Universal will obtain marketing… Read more . . .
-
Milestone Pharmaceuticals says that it completed a Type A meeting with the FDA and subsequently submitted its response to the agency’s complete response letter regarding Milestone’s NDA for Cardamyst etripamil nasal spray for the treatment of… Read more . . .
-
Insmed has announced that a Phase 2b study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension met its primary endpoint, demonstrating a 35% reduction from baseline in pulmonary vascular resistance. The company said… Read more . . .
-
Startup Mosanna Therapeutics announced that it has closed a $80 million Series A financing that will fund Phase 2 development of the company’s MOS118 nasal spray for the treatment of obstructive sleep apnea. Mosanna also announced the… Read more . . .
-
Transpire Bio announced that it has acquired an exclusive license to develop Suzhou Intragrand Pharma’s ITG-1052, a PDE4 inhibitor, as an inhaled therapeutic for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases. The… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA